• Naloxone is a pure opioid antagonist that exerts its effect by competitive inhibition at the opioid receptor sites. It prevents or reverses the effects of opioids, including respiratory depression, sedation and hypotension. In the absence of opioids, it exhibits essentially no pharmacological activity.

Pharmacology Review

  • Reversal of respiratory depression in a suspected narcotic overdose.
  • Hypersensitivity to Naloxone
 Precautions / Notes
  • Polypharmacy overdose.
  • Half-life of naloxone is < 1 hour; repeat doses may be required to maintain effect with longer acting opioids and those with active metabolites (e.g. methadone, diphenoxylate, codeine). Observe patients who respond to naloxone for 2-3 hours after administration for signs of re-narcotisation.
  • Response to Naloxone is rapid; reconsider diagnosis if there is a failure to respond to 2 mg Naloxone.
  • Patients may be aggressive post Naloxone and administration due to hypoxia. Scene safety and personal safety are paramount.
  • IN naloxone is only for EMT scope only, unless no other routes available. For more information, see here.


  • Do NOT dilute in general

IV / IO:

  • Dilute 400microg in 1mL with 9mL NaCl 0.9% to produce 40microg/1mL
 Weight-based Calculations
IM  Naloxone
Presentation: mcg/mL
Calculated dose:  in
Calculated dose:  to  in  to
IV  Naloxone
Presentation: mcg/mL
Calculated dose:  to  in  to
Calculated dose:  in
IV  Naloxone  [Repeat]
Presentation: mcg/mL
Calculated dose: Up to  in


  • IM/IV/IO:
    • 0.4-0.8 mg (400-800 microg) repeat dose every 2 minutes as required, titrated to clinical response to a maximum of 10 mg.
  • IN: 
    • One spray (1.8 mg) of Nyxoid® into nostril.
    • Repeat at 2 minutes in opposite nostril if the patient does not respond.


  • IM/IV/IO:
    • 0.01 mg/kg (10 microg/kg, maximum dose 0.4 mg (400 microg), repeat every 2-3 minutes minutes as required, titrated to clinical response.
    • If high suspicion of overdose, a 0.1 mg/kg (100 microg/kg) dose (maximum 2 mg) may be given following a lack of response to initial dose.
  • IN: 
    • One spray (1.8mg) of Nyxoid® into nostril.
    • Repeat dose after 2 minutes if patient does not respond.
 Special Considerations

Withdrawal symptoms such as:

  • Aggression
  • Agitation
  • Nausea/vomiting
  • Dilated pupils and lacrimation

Take-Home-Naloxone (THN)

  • Total dispensed amount (3.6 mg - 2x 1.8 mg Sprays + Box with Instructions)
  • For patients that have required Naloxone, every attempt should be made to convince the 'at risk' patient to be transported to a healthcare facility.
  • Where attempts prove futile, IN Naloxone - Nyxoid® could be left with the patient. This is to avoid the risk of opioid related respiratory depression due to the short half-life of Naloxone.
  • In such circumstances please ensure to document leaving Nyxoid® with the person or a responsible other person in the PnT / ePCR.
  • Due to our SASA requirements, clinicians cannot supply scheduled medicines to persons who are not St John WA patients.

0.4 mg (400 microg) in 1 mL vial



Each device of Nyxoid nasal spray contains one spray (100 µL). Each dose of 100 µL contains 1.8 mg naloxone.
Current mode:
Extended Care:
Colour assist:


Document Control

Clinical Services

Responsible Manager
Head of Clinical Services


Issue Date

Expiry Date

Clinical Resources Website

St John Ambulance Western Australia Ltd (ABN 55 028 468 715) (St John WA) operates ambulance and other pre-hospital clinical services. St John WA’s Clinical Resources, including its Clinical Practice Guidelines (Clinical Resources), are intended for use by credentialed St John WA staff and volunteers when providing clinical care to patients for or on behalf of St John WA, within the St John WA Clinical Governance Framework, and only to the extent of the clinician’s authority to practice.

Other users – Terms of Use

The content of the St John WA Clinical Resources is provided for information purposes only and is not intended to serve as health, medical or treatment advice. Any user of this website agrees to be bound by these Terms of Use in their use of the Clinical Resources.

St John WA does not represent or warrant (whether express, implied, statutory, or otherwise) that the content of the Clinical Resources is accurate, reliable, up-to-date, complete or that the information contained is suitable for your needs or for any particular purpose. You are responsible for assessing whether the information is accurate, reliable, up-to-date, authentic, relevant, or complete and where appropriate, seek independent professional advice.

St John WA expressly prohibits use of these Clinical Resources to guide clinical care of patients by organisations external to St John WA, except where these organisations have been directly engaged by St John WA to provide services. Any use of the Clinical Resources, with St John WA approval, must attribute St John WA as the creator of the Clinical Resources and include the copyright notice and (where reasonably practicable) provide a URL/hyperlink to the St John WA Clinical Resources website. 

No permission or licence is granted to reproduce, make commercial use of, adapt, modify or create derivative works from these Clinical Resources. For permissions beyond the scope of these Terms of Use, including a commercial licence, please contact medservices@stjohnambulance.com.au

Where links are provided to resources on external websites, St John WA:

  • Gives no assurances about the quality, accuracy or relevance of material on any linked site;
  • Accepts no legal responsibility regarding the accuracy and reliability of external material; and
  • Does not endorse any material, associated organisation, product or service on other sites.

Your use of any external website is governed by the terms of that website, including any authorisation, requirement or licence for use of the material on that website.

To the maximum extent permitted by law, St John WA excludes liability (including liability in negligence) for any direct, special, indirect, incidental, consequential, punitive, exemplary or other loss, cost, damage or expense arising out of, or in connection with, use or reliance on the Clinical Resources (including without limitation any interference with or damage to a user’s computer, device, software or data occurring in connection with such use).


Please read this cookie policy carefully before using Clinical Resources from St John WA.

The cookies used on this site are small and completely anonymous pieces of information and are stored on your computer or mobile device. The data that the cookies contain identify your user preferences (such as your preferred text size, scope / skill level preference and Colour Assist mode, among other user settings) so that they can be recalled the next time that you visit a page within Clinical Resources. These cookies are necessary to offer you the best and most efficient possible experience when accessing and navigating through our website and using its features. These cookies do not collect or send analytical information back to St John WA.

Clinical Resources does integrate with Google Analytics and any cookies associated with this service enable us (and third-party services) to collect aggregated data for statistical purposes on how our visitors use this website. These cookies do not contain personal information such as names and email addresses and are used to help us improve your user experience of the website.

If you want to restrict or block the cookies that are set by our website, you can do so through your browser setting. Alternatively, you can visit www.internetcookies.com, which contains comprehensive information on how to do this on a wide variety of browsers and devices. You will find general information about cookies and details on how to delete cookies from your device. If you have any questions about this policy or our use of cookies, please contact us.

St John Ambulance Western Australia Ltd © Copyright 2020, All Rights Reserved

Terms of Use | Privacy Policy | Copyright Statement & Disclaimer